Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Cannon

Showing results (391-400 of 706) with videos related to

Pageof 71
Sort By:
American Heart Journal|January 31, 2006
Predicting a late positive serum troponin in initially troponin-negative patients with non-ST-elevation acute coronary syndrome: clinical predictors and validated risk score results from the TIMI IIIB and GUSTO IIA studiesJames L Januzzi, L Kristin Newby, Sabina A Murphy, et al.
Cancer|October 13, 2006
Complications of combined modality treatment of primary lower extremity soft-tissue sarcomasChristopher P Cannon, Matthew T Ballo, Gunar K Zagars, et al.
European Heart Journal. Acute Cardiovascular Care|April 6, 2016
Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: A Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudyEvangelos Giannitsis, Lars Wallentin, Stefan K James, et al.
Circulation|July 10, 2002
Elevations in troponin T and I are associated with abnormal tissue level perfusion: a TACTICS-TIMI 18 substudy. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial InfarctionGraham C Wong, David A Morrow, Sabina Murphy, et al.
Diabetologia|March 5, 2021
Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trialDavid Z I Cherney, Bernard Charbonnel, Francesco Cosentino, et al.
The New England Journal of Medicine|March 10, 2004
Intensive versus moderate lipid lowering with statins after acute coronary syndromesChristopher P Cannon, Eugene Braunwald, Carolyn H McCabe, et al.
Critical Pathways in Cardiology|March 15, 2008
Early invasive strategy improves outcomes in patients with acute coronary syndrome with previous coronary artery bypass graft surgery: a report from TACTICS-TIMI 18Aaron D Kugelmass, Saihari Sadanandan, Nasser Lakkis, et al.
Kidney International Reports|April 18, 2023
Effects of Ertugliflozin on Kidney Outcomes in Patients With Heart Failure at Baseline in the Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes (VERTIS CV) TrialDavid Z I Cherney, Francesco Cosentino, Darren K McGuire, et al.
The American Journal of Medicine|July 4, 2012
Age and gender differences in quality of care and outcomes for patients with ST-segment elevation myocardial infarctionSripal Bangalore, Gregg C Fonarow, Eric D Peterson, et al.
Atherosclerosis|July 27, 2019
Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus controlAntonio J Vallejo-Vaz, Kausik K Ray, Henry N Ginsberg, et al.
Pageof 71

Showing results (391-400 of 706) with videos related to

Sort By:
Pageof 71
American Heart Journal|January 31, 2006
Predicting a late positive serum troponin in initially troponin-negative patients with non-ST-elevation acute coronary syndrome: clinical predictors and validated risk score results from the TIMI IIIB and GUSTO IIA studiesJames L Januzzi, L Kristin Newby, Sabina A Murphy, et al.
Cancer|October 13, 2006
Complications of combined modality treatment of primary lower extremity soft-tissue sarcomasChristopher P Cannon, Matthew T Ballo, Gunar K Zagars, et al.
European Heart Journal. Acute Cardiovascular Care|April 6, 2016
Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: A Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudyEvangelos Giannitsis, Lars Wallentin, Stefan K James, et al.
Circulation|July 10, 2002
Elevations in troponin T and I are associated with abnormal tissue level perfusion: a TACTICS-TIMI 18 substudy. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial InfarctionGraham C Wong, David A Morrow, Sabina Murphy, et al.
Diabetologia|March 5, 2021
Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trialDavid Z I Cherney, Bernard Charbonnel, Francesco Cosentino, et al.
The New England Journal of Medicine|March 10, 2004
Intensive versus moderate lipid lowering with statins after acute coronary syndromesChristopher P Cannon, Eugene Braunwald, Carolyn H McCabe, et al.
Critical Pathways in Cardiology|March 15, 2008
Early invasive strategy improves outcomes in patients with acute coronary syndrome with previous coronary artery bypass graft surgery: a report from TACTICS-TIMI 18Aaron D Kugelmass, Saihari Sadanandan, Nasser Lakkis, et al.
Kidney International Reports|April 18, 2023
Effects of Ertugliflozin on Kidney Outcomes in Patients With Heart Failure at Baseline in the Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes (VERTIS CV) TrialDavid Z I Cherney, Francesco Cosentino, Darren K McGuire, et al.
The American Journal of Medicine|July 4, 2012
Age and gender differences in quality of care and outcomes for patients with ST-segment elevation myocardial infarctionSripal Bangalore, Gregg C Fonarow, Eric D Peterson, et al.
Atherosclerosis|July 27, 2019
Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus controlAntonio J Vallejo-Vaz, Kausik K Ray, Henry N Ginsberg, et al.
Pageof 71